Guidelines increasingly highlight the importance of multifactorial management in type 2
diabetes, in contrast to the more traditional focus on glycemic control. Semaglutide, a …

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor
management reduces the likelihood of late-stage diabetic complications. Guidelines …

Oral semaglutide (Rybelsus®) is a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-
1RA) with 94% homology to human GLP-1. It is the first GLP-1RA developed for oral …

Background Regulatory guidance specifies the need to establish cardiovascular safety of
new diabetes therapies in patients with type 2 diabetes in order to rule out excess …

Aims To assess the efficacy and safety of semaglutide, a recently approved glucagon‐like
peptide 1 receptor agonist (GLP‐1 RA) for type 2 diabetes. Materials and methods We …

Importance Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the
treatment of type 2 diabetes and are all currently available as an injection. Objectives To …

Aim Glucagon‐like peptide‐1 receptor agonists improve glycaemic control: some are now
available as oral and subcutaneous formulations, and some have indications for reducing …

Objective: The purpose of this article is to review the pharmacological characteristics and
clinical evidence of oral semaglutide for the treatment of type 2 diabetes mellitus (T2DM) …

Background Despite a broad range of pharmacological options for the treatment of type 2
diabetes, optimum glycaemic control remains challenging for many patients and new …

The first tablet formulation of a glucagon-like peptide-1 receptor agonist (GLP-1RA), oral
semaglutide, was approved in September 2019 for the treatment of adults with type 2 …